title: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
abstract: Proteinuria is a risk factor for progression of chronic renal failure. A model of proteinuria-associated tubulointerstitial injury was developed and was used to examine the therapeutic effect of rapamycin. Two studies were performed. In study A, proteinuric rats were given sheep anti-Fx1A to induce experimental membranous nephropathy; control rats received normal sheep serum. Four weeks later, groups were subdivided and underwent laparotomy alone (two kidneys), nephrectomy alone (one kidney), or nephrectomy with polectomy (0.6 kidney). Renal function and morphology were evaluated 4 wk later. Whereas control rats never developed proteinuria, anti-Fx1A induced severe proteinuria. Proteinuria was unaffected by renal mass reduction. Proteinuric rats developed tubulointerstitial disease that was most severe in rats with 0.6 kidneys. Renal function (GFR) was reduced by loss of renal mass and was reduced further in proteinuric rats with 0.6 kidneys. In study B, the effect of rapamycin on the expression of candidate proinflammatory and profibrotic genes and the progression of proteinuria-associated renal disease were examined. All rats received an injection of anti-Fx1A and were nephrectomized and then divided into groups to receive rapamycin or vehicle. Gene expression, renal morphology, and GFR were evaluated after 4, 8, and 12 wk. Rapamycin reduced expression of the proinflammatory and profibrotic genes (monocyte chemotactic protein-1, vascular endothelial growth factor, PDGF, TGF-beta(1), and type 1 collagen). Tubulointerstitial inflammation and progression of interstitial fibrosis that were present in vehicle-treated rats were ameliorated by rapamycin. Rapamycin also completely inhibited compensatory renal hypertrophy. In summary, rapamycin ameliorates the tubulointerstitial disease associated with chronic proteinuria and loss of renal mass.
authors.affiliation: Evans Biomedical Research Center, Room X530, Boston University Medical Center, 650 Albany Street, Boston, MA 02129, USA. bonegio@bu.edu
authors.forename: Ramon G B
authors.initials: RG
authors.lastname: Bonegio
authors.forename: Robert
authors.initials: R
authors.lastname: Fuhro
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Wang
authors.forename: C Robert
authors.initials: CR
authors.lastname: Valeri
authors.forename: Christopher
authors.initials: C
authors.lastname: Andry
authors.forename: David J
authors.initials: DJ
authors.lastname: Salant
authors.forename: Wilfred
authors.initials: W
authors.lastname: Lieberthal
mesh_terms: D000818:Animals; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D005355:Fibrosis / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000276:immunology; D008297:Male; D011507:Proteinuria / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016207:Cytokines; D007166:Immunosuppressive Agents; D020123:Sirolimus